NUAK1-Targeting Candidate Generation through Optimization and Preclinical Advancement

Genome & Company
GENOME & CO

ONCOLOGY | **Candidate**

Product Type	Small molecule
Indication	Fibrotic disorders, Chronic kidney disease (CKD)
Target	NUAK1
MoA(Mechanism of Action)	• NUAK1, an AMPK-related kinase, is upregulated by TGF-β and promotes fibrogenic responses in multiple fibrotic organs. • Inhibition or silencing of NUAK1 reduces TGF-β–mediated profibrotic signaling and decreases fibrosis-associated protein expression. • NUAK1 is a promising therapeutic target for treating fibrosis-related disorders.
Competitiveness	• Fibrotic diseases, including CKD, significantly contribute to global mortality, with current treatments lacking efficacy and safety. • NUAK1 is a first-in-class target that regulates fibrotic progression and addresses unmet medical needs. • With no NUAK1 inhibitors in clinical development, targeting NUAK1 offers strong scientific and commercial potential as a novel antifibrotic strategy.
Development Stage	Candidate
Route of Administration	Oral administration

Any unauthorized distribution or reproduction of this material is strictly prohibited.